Market Overview

Pfizer Invites Public to View and Listen to Webcast of August 27 Conference Call with Analysts and Investors to Review Tafamidis Data Presentation at ESC Congress 2018


Pfizer Inc. invites investors and the general public to view and listen
to a webcast of a conference call with investment analysts on Monday,
August 27, 2018 at 9:00 a.m. EDT. The purpose of the call is to review
the Tafamidis data presentation at the ESC Congress 2018 organized by
the European Society of Cardiology.

To view and listen to the webcast, visit our web site at
Information on accessing and pre-registering for the webcast will be
available at
beginning today. Participants are advised to pre-register in advance of
the conference call.

You can also listen to the conference call by dialing either (855)
895-8759 in the United States and Canada or (503) 343-6044 outside of
the United States and Canada. The password is "ESC".

Visitors to
will be able to view and listen to an archived copy of the webcast of
the conference call.

Disclosure Notice: The webcast may include forward-looking
statements about, among other things, a potential indication for
Tafamidis for the treatment of transthyretin cardiomyopathy (the
"Potential Indication") and Pfizer's rare disease portfolio, including
their potential benefits, our anticipated future operating and financial
performance, business plans and prospects, in-line products and product
candidates, strategic reviews, capital allocation, business-development
plans, the benefits expected from our recent and pending acquisitions
and plans relating to share repurchases and dividends that are subject
to substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including, the ability to meet
anticipated clinical trial commencement and completion dates and
regulatory submission dates, as well as the possibility of unfavorable
clinical trial results, including unfavorable new clinical data and
additional analyses of existing clinical data; the risk that clinical
trial data are subject to differing interpretations, and, even when we
view data as sufficient to support the safety and/or effectiveness of a
product candidate, regulatory authorities may not share our views and
may require additional data or may deny approval altogether; whether
regulatory authorities will be satisfied with the design of and results
from our clinical studies; whether and when any new or supplemental drug
applications may be filed in any jurisdictions for tafamidis for the
Potential Indication; whether and when regulatory authorities in any
such jurisdictions where applications for tafamidis may be pending
(including the application pending with the FDA for the potential
treatment of transthyretin familial amyloid polyneuropathy, for which
the company received a complete response letter in 2012) or filed may
approve any such applications, which will depend on the assessment by
such regulatory authority of the benefit-risk profile suggested by the
totality of the efficacy and safety information submitted, and, if
approved, whether tafamidis will be commercially successful; decisions
by regulatory authorities regarding labeling and other matters that
could affect the availability or commercial potential of tafamidis,
including for the Potential Indication; and competitive developments.

A description of these risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2017 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned "Risk Factors" and "Forward-Looking
Information and Factors That May Affect Future Results", as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at

The forward-looking statements in the webcast speak only as of the
original date of the webcast. Pfizer assumes no obligation to update
forward-looking statements contained in the webcast as the result of new
information or future events or developments.

View Comments and Join the Discussion!